Open AccessNiclosamide and its derivative DK‐520 inhibit RANKL‐induced osteoclastogenesis
Author(s) -
Jiao Yurui,
Chen Chenglong,
Hu Xijian,
Feng Xu,
Shi Zhenqi,
Cao Jie,
Li Qing,
Zhu Yikun
Publication year - 2020
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12921
Subject(s) - niclosamide , chemistry , rankl , derivative (finance) , microbiology and biotechnology , pharmacology , biochemistry , biology , activator (genetics) , receptor , business , ecology , finance
DK‐520 is an acyl derivative of Niclosamide that exhibits a significant increase in both the plasma concentration and bioavailability. Like Niclosamide, DK‐520 effectively inhibits the early stages of RANKL‐induced osteoclastogenesis and may be a promising drug candidate for treatment of osteoclast‐related diseases.